Although ICB-mediated downregulation of TNF-α in the presence of late-stage ACM would be a beneficial effect to dampen tumour-promoting inflammatory responses which drive resistance to current standards of neoadjuvant care, particularly in late-stage OGJ tumours which are more resistant to chemo(radio)therapy regimens (O’Sullivan 2018). The gene discussed is TNF; the disease is neoplasm.